<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446783</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2011-010</org_study_id>
    <nct_id>NCT01446783</nct_id>
  </id_info>
  <brief_title>IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients</brief_title>
  <official_title>IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to inject insulin-like growth factor-I (IGF-I) into the patella tendon
      of Ehlers-Danlos patients and healthy controls to evaluate the response in collagen
      synthesis. Furthermore collagen synthesis is measured in muscle connective tissue and in
      skin.

      The hypothesis is that the connective tissue in Ehlers-Danlos patients is more compliant and
      poorer in collagen than healthy controls, but that collagen synthesis can be stimulated by
      IGF-I.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGF-I will be injected with ultrasound guidance to one patella tendon and the other one will
      be injected with saline as control. Injections will be performed double blinded and timed 24
      hours and 6 hours before tissue sampling.

      Collagen synthesis will be measured as fractional synthesis rate based on stabile isotope
      technique using labelled proline.

      10 patients diagnosed with Classical form of Ehlers-Danlos syndrome will be included and
      matched with 10 healthy controls based on age, gender, BMI and activity level.

      The muscle biopsy will be taken from vastus lateralis muscle and the skin biopsy from the
      buttocks. The biopsies will if the size permits it also be used for histology and mRNA
      analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional synthesis rate of collagen in tendon, muscle and skin</measure>
    <time_frame>6 hours</time_frame>
    <description>A flood primed infusion of proline labelled with a stable isotope is used to calculate fractional synthesis rate of collagen in the 3 types of tissues. The infusion continues for 6 hours and tissue sampling is performed afterwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electron microscopy</measure>
    <description>If there is additional tissue in the biopsies a piece will be stored for electron microscopy. In skin and tendon a transverse slice will be evaluated on collagen fibril diameter, form and density. In muscle the amount and appearance of connective tissue will be studied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA</measure>
    <description>From the muscle biopsy a piece will be stored for mRNA analysis if possible. Targets will be collagen types and IGF-I isoforms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Ehlers-Danlos Syndrome, Classic</condition>
  <arm_group>
    <arm_group_label>mecasermin + Ehlers-Danlos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + Ehlers-Danlos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mecasamin + healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + healthy control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mecasermin</intervention_name>
    <description>0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.</description>
    <arm_group_label>mecasermin + Ehlers-Danlos</arm_group_label>
    <arm_group_label>Mecasamin + healthy control</arm_group_label>
    <other_name>Increlex (mecasermin), Ipsen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.</description>
    <arm_group_label>Saline + Ehlers-Danlos</arm_group_label>
    <arm_group_label>Saline + healthy control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Classic form of Ehlers-Danlos syndrome OR healthy matched control

        Exclusion Criteria:

          -  Malignity, cardiac diseases, diabetes, tendinopathy in patella tendons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kjaer, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Sportsmedicine Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Sportsmedicine Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>November 19, 2012</last_update_submitted>
  <last_update_submitted_qc>November 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Rie Harboe Nielsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COL5A1</keyword>
  <keyword>Collagen disorders</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Collagen synthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

